Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
CRANBURY, N.J., May 10, 2017 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present at two upcoming investor conferences:
- Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, NV on Wednesday, May 17, 2017 at 5:00 p.m. P.T.
- UBS Global Healthcare Conference 2017 in New York, NY on Monday, May 22, 2017 at 1:00 p.m. E.T.
A live webcast of both presentations can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044
